News - Page 5
Covid-19 action plan – 2021 update
In line with our previous Covid-19 Action Plan, Newcells Biotech has continued to review and invest in measures to reduce the risk to its staff and…
Read update
Improved in vitro renal tubular drug transport modelling to meet regulatory & development cost challenges
The proximal tubule is key due to its role in the excretion and reabsorption of many xenobiotic compounds. Due to the high costs associated with drug discovery and the…
Read update
Development of a physiologically relevant lung model for understanding SARS-CoV-2 infection
Covid-19 is known to infect the lungs. However, the dynamics of viral infection and replication are poorly understood. Alongside the Liverpool School of Tropical Medicine, we…
Read update
Diagnosing unresolved Stargardt disease using retina-specific splicing isoforms obtained from retinal organoids
At Newcells Biotech, we specialise in the large-scale production of retinal organoids for the purpose of in vitro toxicology efficacy studies and disease modelling. Our differentiation protocols generate organoids which…
Read update
Development of functioning in vitro lung assay for modelling Covid-19 infection
Newcells Biotech, experts in induced pluripotent stem cell (iPSC) differentiation and assay construction, have confirmed their human lung epithelium model as an effective platform…
Read update
Newcells scales up its operations in The Biosphere
Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory
Read update
An overview of vaccine development & sub-types
Vaccination can be regarded as one of biomedicines biggest triumphs. Since Edward Jenner pioneered the smallpox vaccine in 1798, subsequent morbidity and mortality rates have
Read updateBiologics & the kidney – importance of transport & safety assessment
Biologics represent a new modality of drug molecules which is rapidly expanding in market share and in the number of biologics gaining regulatory approval each year. Biologics are defined…
Read update
The Human Cell Atlas – an aid to understanding COVID-19 & a valuable tool in the development of hiPSC models
The outbreak of the novel viral disease, COVID-19, caused by the severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), has led to worldwide health and economic catastrophe.1 Almost 2 million…
Read update
NB testing an in vitro model of the human lung epithelium for application in the fight against SARS-CoV-2
Internationally renowned company, Newcells Biotech, are using their established expertise in human induced pluripotent stem cell (hiPSC) technology to test their existing model of the human lung epithelium as…
Read update
Covid-19 action plan – A message to our customers, collaboration partners & colleagues
As we all come to terms with the extraordinary and rapidly changing global situation caused by Covid-19, I would like to update you on the plans we have in…
Read update
NB win Phase II of CRACK IT Challenge 29: ImmuLiver
Newcells Biotech are excited to announce that they are Phase II contract winners of the NC3Rs-funded CRACK IT Challenge (named ImmuLiver). They have been awarded a further funding to…
Read update
